[1]张学人,倪宬璐,方 荣,等.参附强心汤治疗老年慢性心力衰竭临床研究[J].陕西中医,2022,(5):584-587.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.009]
　ZHANG Xueren,NI Chenglu,FANG Rong,et al.Effect of Shenfu Qiangxin decoction in the treatment of elderly chronic heart failure[J].,2022,(5):584-587.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.009]
点击复制

参附强心汤治疗老年慢性心力衰竭临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年5期
页码:
584-587
栏目:
临床研究
出版日期:
2022-05-05

文章信息/Info

Title:
Effect of Shenfu Qiangxin decoction in the treatment of elderly chronic heart failure
作者:
张学人; 倪宬璐; 方 荣; 施 荣
(上海中医药大学附属曙光医院急诊科,上海 201203)
Author(s):
ZHANG Xueren; NI Chenglu; FANG Rong; SHI Rong
(Department of Emergency,Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
关键词:
慢性心力衰竭;  参附强心汤;  左室射血分数;  左室心肌质量指数;  症状评分
Keywords:
Chronic heart failure;  Shenfu Qiangxin decoction;  LVEF;  LVMI;  Symptom score
分类号:
R 541
DOI:
DOI:10.3969/j.issn.1000-7369.2022.05.009
文献标志码:
A
摘要:
目的:探讨参附强心汤辅助西药治疗老年慢性心力衰竭疗效。方法:选取104例老年慢性心力衰竭患者,以随机数字表法分为研究组和对照组各52例。对照组采用常规西医治疗,研究组在对照组的基础上另给予参附强心汤治疗,持续治疗6个月后观察效果。对比两组中医症状评分、疗效,记录两组心室重构、血生化指标情况,统计治疗期间药物安全性及随访1年期间预后情况。结果:研究组治疗后的中医症状评分低于对照组(P<0.05)。研究组总有效率高于对照组(P<0.05)。两组治疗后的左室射血分数(LVEF)升高,左室心肌质量指数(LVMI)、左室舒张末期内径(LVEDD)均降低(P<0.05); 研究组治疗后的LVMI、LVEDD均低于对照组,LVEF高于对照组(P<0.05)。两组治疗后的sICAM-1、sVCAM-1均低于治疗前(P<0.05),研究组治疗后的sICAM-1、sVCAM-1均低于对照组(P<0.05)。两组总不良反应发生率、总心脏不良事件发生率比较差异无统计学意义(P>0.05)。结论:参附强心汤辅助西药治疗老年慢性心力衰竭可增强临床疗效,改善心室重构、心肌损伤,且安全性及近期预后良好。
Abstract:
Objective:To explore the therapeutic effect of Shenfu Qiangxin decoction assisting western medicine in the treatment of elderly chronic heart failure.Methods:A total of 104 elderly chronic heart failure patients were selected,and they were divided into study group(52 cases)and control group(52 cases)based on random number table method.Control group was given conventional western medicine,and the study group was treated with Shenfu Qiangxin decoction on the basis of the control group.The effect was observed after 6 months of continuous treatment.The symptom scores and curative effects of the two groups of Chinese medicine were compared.Ventricular remodeling and blood biochemical indicators were recorded in the two groups.The drug safety during the treatment and the prognosis during the 1-year follow-up period were counted.Results:The TCM symptom score of the study group after treatment was lower than the control group(P<0.05).The left ventricular ejection fraction(LVEF)after treatment in the two groups was higher than before treatment,left ventricular myocardial mass index(LVMI)and the left ventricular end diastolic diameter(LVEDD)were lower than before treatment(P<0.05).The LVEDD and LVMI of the study group after treatment were lower than the control group,and the LVEF was higher than the control group(P<0.05).The sICAM-1 and sVCAM-1 after treatment in the two groups were lower than before treatment(P<0.05),and the sICAM-1 and sVCAM-1 in the study group after treatment were lower than the control group(P<0.05).There was no statistically significant difference in the incidence of total adverse reactions between the two groups(P>0.05).There was no significant difference in the incidence of total cardiac adverse events between the two groups during the follow-up period(P>0.05).Conclusion:Shenfu Qiangxin decoction assisting western medicine in the treatment of chronic heart failure in the elderly can enhance the clinical efficacy,improve ventricular remodeling and myocardial injury,and has a good safety and short-term prognosis.

参考文献/References:

[1] Tang WH,Li DY,Hazen SL.Dietary metabolism,the gut microbiome,and heart failure[J].Nat Rev Cardiol,2019,16(3):137-154.
[2] 中国康复医学会心血管病预防与康复专业委员会.慢性心力衰竭心脏康复中国专家共识[J].中华内科杂志,2020,59(12):942-952.
[3] House AA,Wanner C,Sarnak MJ,et al.Heart failure in chronic kidney disease:Conclusions from a kidney disease,improving global outcomes(KDIGO)controversies conference[J].Kidney Int,2019,95(6):1304-1317.
[4] Bouwens E,Berg VJ,Akkerhuis KM,et al.Circulating biomarkers of cell adhesion predict clinical outcome in patients with chronic heart failure[J].J Clin Med,2020,9(1):195-198.
[5] 毛静远,朱明军.慢性心力衰竭中医诊疗专家共识[J].中医杂志,2014,55(14):1258.
[6] 李 斐,胡 骏,冯启凡.米力农联合多巴胺对慢性心力衰竭的疗效及对血清CysC、NT-proBNP、IL-6的影响[J].河北医学,2019,25(8):1329-1333.
[7] 王 毅,杨 征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,48(1):64-66.
[8] 高登峰.加味五苓散联合西药治疗慢性心力衰竭疗效及对患者心功能,纤维化指标,炎性因子水平的影响[J].陕西中医,2021,42(2):167-171.
[9] 杨自生,金 琪,简立国.参苓养心汤治疗慢性心衰的疗效及对心功能、活动耐力、NT-ProBNP、hs-CRP的影响[J].陕西中医,2019,40(2):167-170.
[10] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[11] 陈可冀,吴宗贵,朱明军,等.慢性心力衰竭中西医结合诊疗专家共识[J].中国中西医结合杂志,2016,36(2):133-141.
[12] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:25-49.
[13] 凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究[J].陕西中医,2020,41(1):71-74.
[14] 管 颖.老年慢性心力衰竭住院患者营养状况对心室重构的影响[J].中国老年学杂志,2020,40(4):24-27.
[15] 高佳明,吕 明,解微微,等.中医药心脑血管疾病同治的方剂用药规律分析[J].中国中药杂志,2019,44(1):193-198.
[16] 李子凤,倪 青.中医调养在老年糖尿病伴心脑血管疾病中的作用[J].中西医结合心脑血管病杂志,2020,18(7):154-156.
[17] 陈 婵,张 鹏,王 娟,等.射血分数保留和射血分数减低心力衰竭中医四诊及证候特征研究[J].中西医结合心脑血管病杂志,2019,17(7):16-19.
[18] 赵志强,王贤良,张 萍,等.基于前瞻性临床流行病学调查的射血分数正常心力衰竭中医证候特征分析[J].中医杂志,2019,60(9):773-778.
[19] Hao E,Pang G,Du Z,et al.Peach kernel oil downregulates expression of tissue factor and reduces atherosclerosis in apoE knockout mice[J].Int J Mol Sci,2019,20(2):405-410.
[20] 张时文,王 欣,张小军.黄芪多糖对人肺癌细胞迁移的抑制作用机制研究[J].中国临床药理学杂志,2020,36(9):78-81.
[21] 李志立,杨 冰,翟艳敏,等.基于分子对接技术虚拟筛选红花中抗心肌缺血活性组分[J].中国中药杂志,2020,45(12):163-172.
[22] 武 琦,林 娟,刘耀晨,等.基于网络药理学的三七传统功效作用机制研究[J].中草药,2020,51(14):3717-3727.
[23] 邢作英,王永霞,朱明军,等.桂枝甘草汤及其拆方含药血清对豚鼠心室肌细胞L-型钙通道的影响[J].中国中西医结合杂志,2018,38(3):331-335.

相似文献/References:

[1]杨自生,金 琪,简立国.参苓养心汤治疗慢性心衰的疗效及对心功能、活动耐力、 NTProBNP、hsCRP的影响*[J].陕西中医,2019,(2):167.
　YANG Zisheng,JIN Qi,JIAN Liguo..The effect of Shenling Yangxin decoction on chronic heart failure and its effect on cardiac function，activity endurance，NTProBNP and hsCRP[J].,2019,(5):167.
[2]孙 哲,杨 默,石宗华.丹参多酚酸盐与丹参酮治疗慢性心力衰竭临床研究[J].陕西中医,2019,(5):591.
　SUN Zhe,YANG Mo,SHI Zonghua..Clinical effect and mechanism of salvianolate and Tanshinone in the treatment of chronic heart failure[J].,2019,(5):591.
[3]向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究*[J].陕西中医,2019,(8):1085.
　XIANG Zongxing,TUO Wen,QIU Weifeng,et al.Clinical value of Huangqi Baoxin decoction combined with western medicine in the treatment of chronic heart failure[J].,2019,(5):1085.
[4]尚加芬.参芪附仙饮联合盐酸曲美他嗪片辨治慢性心力衰竭心肾阳虚证临床研究[J].陕西中医,2020,(1):38.
[5]陈宗伟,沈志涛,郑振国,等.芪苈强心胶囊配合保元汤加减治疗慢性心力衰竭临床研究*[J].陕西中医,2020,(2):191.
　CHEN Zongwei,SHEN Zhitao,ZHENG Zhenguo,et al.Observation on the effect of Qili Qiangxin capsules assist Baoyuan decoction in the treatment of chronic heart failure[J].,2020,(5):191.
[6]凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究*[J].陕西中医,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
　LING Wang,SUN Siming,WANG Luling,et al.A Study on the quality of life about Wenyang Yiqi Huoxue therapy in the treatment of chronic heart failure[J].,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
[7]朱 杰,林兆奋△,胡 聃,等.中西医结合治疗慢性心力衰竭研究进展*[J].陕西中医,2020,(9):1342.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.046]
[8]刘 薇,张玉焕,李 争.芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J].陕西中医,2021,(1):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
　LIU Wei,ZHANG Yuhuan,LI Zheng.Effects of Qishen Yiqi dropping pills on myocardial protection,inflammatory state and serum cell adhesion molecule level in elderly patients with heart failure caused by qi deficiency and blood stasis[J].,2021,(5):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
[9]黄光明.理中汤加减治疗慢性心力衰竭及对患者血清BNP、IL-10及NOS水平的影响研究[J].陕西中医,2021,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
　HUANG Guangming.Modified Lizhong decoction on clinical symptoms and levels of serum BNP,IL-10 and NOS in patients with chronic heart failure[J].,2021,(5):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
[10]胡 芳,谭明娜,谭小娥,等.加味五苓散联合西药治疗慢性心力衰竭疗效及对患者心功能、纤维化指标、炎性因子水平的影响[J].陕西中医,2021,(2):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]
　HU Fang,TAN Mingna,TAN Xiao'e,et al.Effects of modified Wuling powder combined with western medicine on levels of cardiac function,fibrosis indicators and inflammatory factors in patients with chronic heart failure[J].,2021,(5):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]

备注/Memo

备注/Memo:
基金项目:上海市科学技术委员会科研项目(21Y11920600)
更新日期/Last Update: 2022-05-09